What does the licensing of teplizumab mean for diabetes care?

Quinn, Lauren M; Swaby, Rabbi; Tatovic, Danijela; Narendran, Parth; Besser, Rachel E J; Dayan, Colin M

Quinn, Lauren M; Swaby, Rabbi; Tatovic, Danijela; Narendran, Parth; Besser, Rachel E J; Dayan, Colin M.

Afiliação

Quinn LM; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.
Swaby R; Wellcome Centre for Human Genetics, University of Oxford, Oxford, UK.
Tatovic D; Wellcome Centre for Human Genetics, University of Oxford, Oxford, UK.
Narendran P; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.
Besser REJ; Department of Diabetes, University Hospitals of Birmingham, Birmingham, UK.
Dayan CM; Wellcome Centre for Human Genetics, University of Oxford, Oxford, UK.

Diabetes Obes Metab ; 25(8): 2051-2057, 2023 08.

Article em En | MEDLINE | ID: mdl-36999237

Assuntos

Diabetes Mellitus Tipo 1; Humanos; Diabetes Mellitus Tipo 1/tratamento farmacológico; Hipoglicemiantes/efeitos adversos; Anticorpos Monoclonais Humanizados/uso terapêutico; Autoanticorpos

Palavras-chave

autoantibodies; screening; teplizumab; type 1 diabetes

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Diabetes Mellitus Tipo 1 Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google